Equity · Healthcare
LRMR
NASDAQLarimar Therapeutics (LRMR)
The line runs 2.70 USD on 8 October through 2.70 USD on 12 November, on a scale from 1.5 to 3.0. Days the market did not trade hold the previous close, flat.
- Market cap
- 282.5M USD
- 52-week range
- 1.99 USD – 6 USD
- Avg volume
- 165.9K
as of Nov 12, 2026
Have Larimar Therapeutics (LRMR) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Larimar Therapeutics insiders reported 9 open-market purchases and no sales (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 16 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Nov 2026 | SHERMAN JEFFREY WDirector | Buy | 3,289 | 10K USD |
| 16 Nov 2026 | Clayton RussellChief Medical Officer | Buy | 3,322 | 10K USD |
| 12 Nov 2026 | Hamilton Thomas EdwardDirector | Buy | 70,000 | 187K USD |
| 11 Nov 2026 | BEN-MAIMON CAROLEPresident and CEO | Buy | 18,050 | 50K USD |
| 11 Nov 2026 | Celano MichaelChief Financial Officer | Buy | 18,460 | 50K USD |
| 11 Nov 2026 | Harlow John B. Jr.President and COO | Buy | 17,800 | 50K USD |
| 11 Nov 2026 | Shankar GopiChief Development Officer | Buy | 5,000 | 14K USD |
| 11 Nov 2026 | Truitt JosephDirector | Buy | 3,500 | 10K USD |
| 11 Nov 2026 | THOMAS FRANK EDirector | Buy | 8,000 | 22K USD |
| Bought | 9 open-market purchases | 147,421 | $402K |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 29 Sep 2026 | Harlow John B. Jr.President and COO | Award | 50,000 |
Which funds hold Larimar Therapeutics (LRMR)?
7 of the 45 institutional funds we track reported a Larimar Therapeutics position for the quarter ended 30 Sep 2026 — a combined 22.9M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Held (±25%) | 2,240,623 | 7.2M USD | −5.5% |
| Marshall Wace | Held (±25%) | 2,195,954 | 7.0M USD | +9.1% |
| Millennium Management | Added | 1,669,047 | 5.3M USD | +25.2% |
| D. E. Shaw & Co. | New position | 568,598 | 1.8M USD | |
| Two Sigma Investments | Held (±25%) | 236,133 | 754K USD | |
| Renaissance Technologies | Trimmed | 184,043 | 588K USD | −38.1% |
| Citadel Advisors | Trimmed | 66,377 | 212K USD | −95.4% |
| Balyasny Asset Management | Exited | |||
| Man Group | Exited | |||
| Point72 Asset Management | Exited |
What has been filed or recorded for Larimar Therapeutics (LRMR)?
The filings we hold for Larimar Therapeutics, newest first: 7 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 3 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 435 shares | 1K USD notional · <0.001% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 431 shares | 978 USD notional · <0.001% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 105 shares | 223 USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 443 shares | 882 USD notional · <0.001% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 49,053 shares | 106K USD notional · 0.047% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 8,670 shares | 22K USD notional · 0.008% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 699 shares | 2K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Financials | Total assets | 140.5M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 101.5M USD | at period end |
| 31 Dec 2025 | Financials | Net income | −165.7M USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.61 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.41 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.46 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.32 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.24 USD | |
| 30 Jun 2024 | Quarterly earnings | Q2 2024 reported | EPS −0.34 USD | |
| 31 Mar 2024 | Quarterly earnings | Q1 2024 reported | EPS −0.27 USD | |
| 31 Dec 2023 | Annual report | FY 2023 reported | EPS −0.84 USD |
What do people ask about Larimar Therapeutics (LRMR)?
What did Larimar Therapeutics shares close at?2.70
Larimar Therapeutics closed at 2.70 USD on 12 Nov 2026, down 1.46% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Larimar Therapeutics’ market cap?282.5M
Larimar Therapeutics is worth 282.5M USD by market value as of 12 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Larimar Therapeutics insiders bought or sold shares recently?9 purchases
In the 90 days to 22 Nov 2026, Larimar Therapeutics insiders reported 9 open-market purchases and no sales (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Larimar Therapeutics?7 of 45
7 of the 45 funds we track reported a Larimar Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Marshall Wace and Millennium Management. See Funds
When did Larimar Therapeutics last report earnings?−0.61
Larimar Therapeutics last reported earnings on 30 Sep 2025 for Q3 2025, with EPS of −0.61 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words